Literature DB >> 74554

Safety of tamoxifen.

J S Patterson, M Baum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 74554     DOI： 10.1016/s0140-6736(78)90053-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Tamoxifen and liver damage.

Authors:  A M Blackburn; S A Amiel; R R Millis; R D Rubens
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-04

Review 2.  Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

3.  Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.

Authors:  J Bishop; R Murray; L Webster; P Pitt; K Stokes; A Fennessy; I Olver; G Leber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.

Authors:  A Valentin-Opran; G Eilon; S Saez; G R Mundy
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

5.  Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.

Authors:  S Maruyama; C Hirayama; J Abe; J Tanaka; K Matsui
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

6.  Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.

Authors:  J H Glick; R H Creech; S Torri; C Holroyde; H Brodovsky; R B Catalano; M Varano
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

Review 7.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.